Literature DB >> 23627681

Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old.

Nelson Wolosker1, Claudio Schvartsman, Mariana Krutman, Taiz Pereira Dozono Almeida Campbell, Paulo Kauffman, Jose Ribas M de Campos, Pedro Puech-Leão.   

Abstract

The effects of oxybutynin for treating hyperhidrosis in children are still unknown. Therefore the aim of this study was to investigate the effects of oxybutynin on improving symptoms of hyperhidrosis and quality of life (QOL) in children with palmar hyperhidrosis (PH). Forty-five children ages 7-14 years with PH were evaluated 6 weeks after protocol treatment with oxybutynin. QOL was evaluated before and after treatment using a validated clinical questionnaire. More than 85% of the children with PH treated with oxybutynin experienced moderate or greater improvement in the level of sweating and 80% experienced improvement in QOL. Children who initially presented with very poor QOL were those who benefited most from oxybutynin therapy. Side effects occurred in 25 children (55.5%) and were mainly dry mouth. Only one patient had neurologic symptoms, which was reported as drowsiness. Oxybutynin is an effective treatment option for children with PH because it improves clinical symptoms and QOL. Further studies are required to determine the long-term outcomes of treatment with oxybutynin.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23627681     DOI: 10.1111/pde.12142

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  10 in total

Review 1.  Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art.

Authors:  Anna Campanati; Stamatis Gregoriou; George Kontochristopoulos; Annamaria Offidani
Journal:  Skin Appendage Disord       Date:  2015-01-30

2.  Long-term results of oxybutynin treatment for palmar hyperhidrosis.

Authors:  Nelson Wolosker; Marcelo Passos Teivelis; Mariana Krutman; Rafael P de Paula; José R M de Campos; Paulo Kauffman; Pedro Puech-Leão
Journal:  Clin Auton Res       Date:  2014-11-27       Impact factor: 4.435

Review 3.  Treatment of Hyperhidrosis: An Update.

Authors:  Mattias A S Henning; Dorra Bouazzi; Gregor B E Jemec
Journal:  Am J Clin Dermatol       Date:  2022-07-01       Impact factor: 6.233

4.  Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults.

Authors:  Nicholas V Nguyen; Jane Gralla; James Abbott; Anna L Bruckner
Journal:  Pediatr Dermatol       Date:  2018-01-15       Impact factor: 1.588

5.  Symptoms of anxiety and depression in patients with primary hyperhidrosis and its association with the result of clinical treatment with oxybutynin.

Authors:  Débora Yumi Ferreira Kamikava; Nelson Wolosker; Marcelo Fiorelli Alexandrino da Silva; José Ribas Milanez de Campos; Pedro Puech-Leão
Journal:  Clinics (Sao Paulo)       Date:  2021-06-28       Impact factor: 2.365

6.  Epidemiologic analysis of prevalence of the hyperhidrosis.

Authors:  Fernanda Alvarenga Estevan; Marina Borri Wolosker; Nelson Wolosker; Pedro Puech-Leão
Journal:  An Bras Dermatol       Date:  2017 Sep-Oct       Impact factor: 1.896

Review 7.  Oxybutynin as an alternative treatment for hyperhidrosis.

Authors:  Sergio Delort; Evaldo Marchi; Marcos Antônio Corrêa
Journal:  An Bras Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.896

8.  Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions.

Authors:  Stamatios Gregoriou; Polytimi Sidiropoulou; Georgios Kontochristopoulos; Dimitrios Rigopoulos
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-10-04

9.  Einsteins? Role in clinical research.

Authors:  Nelson Wolosker; Luiz Vicente Rizzo; Cláudio Schvartsman
Journal:  Einstein (Sao Paulo)       Date:  2014-04

10.  Curative effect of minimally invasive surgery on palmar and foot hyperhidrosis and its influence on serum-related cytokines and immunoglobulins.

Authors:  Wei Xi Li; Yong Kun Li; Hai Tao Lin
Journal:  Exp Ther Med       Date:  2018-02-15       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.